These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 8108873)

  • 21. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
    Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
    Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective randomized comparison of prophylactic ALG and OKT3 in cadaver kidney allograft recipients.
    Hanto DW; Jendrisak MD; McCullough CS; So SK; Marsh JW; Rush T; Michalski S; Phelan D; Mohanakumar T
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1050-1. PubMed ID: 1899150
    [No Abstract]   [Full Text] [Related]  

  • 23. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation.
    Norman DJ; Kahana L; Stuart FP; Thistlethwaite JR; Shield CF; Monaco A; Dehlinger J; Wu SC; Van Horn A; Haverty TP
    Transplantation; 1993 Jan; 55(1):44-50. PubMed ID: 8420063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients.
    Barber WH; Mankin JA; Laskow DA; Deierhoi MH; Julian BA; Curtis JJ; Diethelm AG
    Transplantation; 1991 Jan; 51(1):70-5. PubMed ID: 1987708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients.
    Schulak JA; Mayes JT; Moritz CE; Hricik DE
    Transplantation; 1990 Feb; 49(2):327-32. PubMed ID: 2407003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized trial comparing cyclosporine with antilymphoblast-globulin-azathioprine for renal allograft recipients. Results at 2 1/2-6 years.
    Johnson CP; Simmons RL; Sutherland DE; Canafax DM; Ascher NL; Payne WD; Flick B; Najarian JS; Fryd DS
    Transplantation; 1988 Feb; 45(2):380-5. PubMed ID: 3278431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
    Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.
    Najarian JS; Fryd DS; Strand M; Canafax DM; Ascher NL; Payne WD; Simmons RL; Sutherland DE
    Ann Surg; 1985 Feb; 201(2):142-57. PubMed ID: 3882063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individualization of immediate posttransplant immunosuppression. The value of antilymphocyte globulin in patients with delayed graft function.
    Matas AJ; Tellis VA; Quinn TA; Glicklich D; Soberman R; Veith FJ
    Transplantation; 1988 Feb; 45(2):406-9. PubMed ID: 3278434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of delayed function on recipients of cadaver renal allografts. A study of 158 patients randomized to cyclosporine or ALG-azathioprine.
    Canafax DM; Torres A; Fryd DS; Heil JE; Strand MH; Ascher NL; Payne WD; Sutherland DE; Simmons RL; Najarian JS
    Transplantation; 1986 Feb; 41(2):177-81. PubMed ID: 3511581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphocytotoxin.
    Lobo PI; Spencer CE; Stevenson WC; Pruett TL
    Transplantation; 1995 Feb; 59(3):357-60. PubMed ID: 7871565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation. Results of a randomized prospective study.
    Novick AC; Hwei HH; Steinmuller D; Streem SB; Cunningham RJ; Steinhilber D; Goormastic M; Buszta C
    Transplantation; 1986 Aug; 42(2):154-8. PubMed ID: 3526655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of OKT3 monoclonal antibody and anti-thymocyte globulin in the treatment of steroid-resistant acute allograft rejection in pediatric renal transplants.
    Mochon M; Kaiser B; Palmer JA; Polinsky M; Flynn JT; Caputo GC; Baluarte HJ
    Pediatr Nephrol; 1993 Jun; 7(3):259-62. PubMed ID: 8518094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Excellent outcome with a calcium channel blocker-supplemented immunosuppressive regimen in cadaveric renal transplantation. A potential strategy to avoid antibody induction protocols.
    Suthanthiran M; Haschemeyer RH; Riggio RR; Adubor C; Friedman GS; Cheigh JS; Wang JC; Fotino M; Stubenbord WT; Saal SD
    Transplantation; 1993 May; 55(5):1008-13. PubMed ID: 8497873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The effects of the treatment for acute rejection with OKT3 monoclonal antibody treatment on the long-term results of cadaveric kidney transplantation].
    Kinukawa T; Hattori R; Ohshima S; Matsuura O; Takeuchi N; Fujita T; Nishiyama N; Ono Y; Sahashi M; Yamada S
    Nihon Hinyokika Gakkai Zasshi; 1993 Oct; 84(10):1851-6. PubMed ID: 8255049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. OKT3 treatment of steroid-resistant renal allograft rejection.
    Thistlethwaite JR; Gaber AO; Haag BW; Aronson AJ; Broelsch CE; Stuart JK; Stuart FP
    Transplantation; 1987 Feb; 43(2):176-84. PubMed ID: 3544373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delayed response to orthoclone OKT3 treatment for renal allograft rejection resistant to steroid and antilymphocyte globulin.
    Oh CS; Sollinger HW; Stratta RJ; Kalayoglu M; Belzer FO
    Transplantation; 1988 Jan; 45(1):65-7. PubMed ID: 3276065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation.
    Bock HA; Gallati H; Zürcher RM; Bachofen M; Mihatsch MJ; Landmann J; Thiel G
    Transplantation; 1995 Mar; 59(6):830-40. PubMed ID: 7701577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
    Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beneficial effect of concomitant induction with antilymphoblast globulin, cyclosporine, and steroids on long-term renal allograft outcome.
    Koga A; Moreso FJ; Seron D; Gil-Vernet S; Cruzado JM; Castelao AM; Grinyó JM
    Transplant Proc; 2004 Jun; 36(5):1305-7. PubMed ID: 15251318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.